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Background: Fluoroquinolones are the backbone of multidrug resistant tuberculosis treat-
ment regimens. Despite the high burden of multidrug resistant tuberculosis in the country,
little is known about drug resistance patterns, prevalence, and predictors of ﬂuoro-
quinolones resistance among multidrug resistant tuberculosis patients from Pakistan.
Objective: To evaluate drug resistance patterns, prevalence, and predictors of ﬂuoro-
quinolones resistance in multidrug resistant tuberculosis patients.
Methods: This was a cross-sectional study conducted at a programmatic management unit
of  drug resistant tuberculosis, Lady Reading Hospital Peshawar, Pakistan. Two hundred
and forty-three newly diagnosed multidrug resistant tuberculosis patients consecutively
enrolled for treatment at study site from January 1, 2012 to July 28, 2013 were included in the
study. A standardized data collection form was used to collect patients’ socio-demographic,
microbiological, and clinical data. SPSS 16 was used for data analysis.
Results: High degree of drug resistance (median 5 drugs, range 2–8) was  observed. High pro-
portion of patients was resistant to all ﬁve ﬁrst-line anti-tuberculosis drugs (62.6%), and
more than half were resistant to second line drugs (55.1%). The majority of the patients
were  oﬂoxacin resistant (52.7%). Upon multivariate analysis previous tuberculosis treat-
ment at private (OR = 1.953, p = 0.034) and public private mix (OR = 2.824, p = 0.046) sectors
were predictors of oﬂoxacin resistance.
Conclusion: The high degree of drug resistance observed, particularly to ﬂuoroquinolones,
is  alarming. We  recommend the adoption of more restrictive policies to control non-
prescription sale of ﬂuoroquinolones, its rational use by physicians, and training doctors inboth  private and public–p
resistant Mycobacterium tu
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413-8670/© 2015 Elsevier Editora Ltda. All rights reserved.rivate mix sectors to prevent further increase in ﬂuoroquinolones
berculosis strains.
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289 drug resistant TB patients
were enrolled at the study site
from January 1, 2012 to
 July 31, 2013
17 patients with history
of MDR-TB treatment
were excluded
243 MDR-TB patients were included
in the study
29 (10 mono-drug
resistant, 6 poly-drug
resistant and 13 XDR-TB
patients) were excluded
Fig. 1 – Inclusion and exclusion of study patients. MDR-TB,
multidrug resistant tuberculosis; XDR-TB, extensive drug42  b r a z j i n f e c t d
Introduction
Multidrug resistant tuberculosis (MDR-TB) deﬁned as resis-
tance to both isoniazid (H, INH) and rifampicin (R, Rif) is
a major barrier to achieve successful TB control. Both INH
and Rif are the most effective anti-TB drugs and the back-
bone of ﬁrst line anti-TB treatment. Resistance to INH and
Rif leads treatment with less potent, more  toxic and expen-
sive second-line anti-TB drugs (SLD). Fluoroquinolones (FQ)
— broad spectrum antibiotics — have been shown to be use-
ful in TB treatment — have been used in TB care since 1984,
and have become integral part of drug resistant TB treatment
regimens.1 Various studies have reported positive associa-
tions between FQ resistance and poor treatment outcomes in
MDR-TB.2–5 Unfortunately, Pakistan in addition to be the 5th
highest country of TB burden also harbors the largest popu-
lation of MDR-TB patients in Eastern Mediterranean Region
of WHO.  It is estimated that 9900 (95% conﬁdence interval
[CI]: 6400–13,300) new MDR-TB cases emerged in Pakistan in
2013 with an estimated proportion of 4.3% (95% CI: 2.8–5.7)
of new cases and 19% (95% CI: 14–25) of previously treated
TB cases.6 This situation is further worsened by reportedly
increased FQ resistance in drug resistant TB in the country.7,8
Few studies from Pakistan have evaluated the prevalence of
FQ resistance in MDR-TB patients,7–10 but to the best of our
knowledge none has evaluated predictors of FQ resistance
in MDR-TB patients. Therefore, the present study was con-
ducted with the aim to evaluate patterns of drug resistance,
prevalence, and predictors of FQ resistance among MDR-TB
patients.
Materials  and  methods
Study  design  and  settings
This was a cross-sectional study conducted at a program-
matic management unit of drug resistant TB (PMDT), Lady
Reading Hospital (LRH) Peshawar, Pakistan. At the time of
study initiation, PMDT unit LRH was the only center in Khyber
Pukhtoonkhwa (one of the four provinces of Pakistan) where
drug resistant TB was treated. All MDR-TB patients consecu-
tively enrolled for treatment at the study site from January 1,
2012 to July 28, 2013 were included in the study. Since Octo-
ber 1, 2012 data were collected prospectively while before
October 1, 2012 data were collected retrospectively. Patients
with mono, poly, and extensive drug resistant TB (XDR-TB)
and/or history of previous treatment of drug resistant TB were
excluded.
Drug resistant TB (DR-TB) suspects referred to the study
site were initially evaluated with two sputum samples for
acid fast bacilli (AFB) by direct sputum smear microscopy
using Ziehl Neelsen staining method and GeneXpert Sys-
tem’s MTB/Rif (Mycobacterium tuberculosis/rifampicin). Upon
positive smear microscopy and GeneXpert System’s MTB/Rif,
sputum samples were sent to Aga Khan University Hospi-
tal Laboratory for sputum culture and DST. Susceptibility
testing for isoniazid (H), rifampicin (R), ethambutol (E), strep-
tomycin (S), oﬂoxacin (Ofx), amikacin (Am), kanamycin (Km),resistant tuberculosis.
ethionamide (Eto), and capreomycin (Cm) was conducted
by using agar proportion method on enriched Middle brook
7H10 medium (BBL, Beckton Dickinson). Pyrazinamide (PZA, Z)
susceptibility test was carried out by using BACTEC Mycobac-
terial Growth Indicator Tube (Becton Dickinson Diagnostics,
Sparks, MD, USA) in accordance with manufacturer’s instruc-
tions. A standardized data collection form was used to collect
patients’ socio-demographic, microbiological, and clinical
data.
Statistical  analysis
Statistical Package for Social Sciences (SPSS 16) was used for
data analysis. Means and standard deviations were calcu-
lated for continuous variables, whereas categorical variable
were presented as frequencies and percentages. Chi-squared
test was used to observe association between categorical
variables. Multivariate logistic regression analysis with Wald
statistical criteria using the backward elimination method
was used to obtain a ﬁnal model describing the predictors
FQ resistance. A p-value of <0.05 was considered statis-
tically signiﬁcant. Relevant variables with p-value <0.2 in
univariate analysis were included in multivariate analysis. We
checked correlation among variables entered in multivariate
analysis.
Ethical  approval
The study was approved by the Research and Ethics Commit-
tee of Postgraduate Medical Institute, Peshawar, Pakistan. Prior
to beginning of the study, written consent was taken from
patients who were able to do so. In case of illiteracy the pur-
pose of study was explained to the patients in their native
language, and next a kin or treatment supporter gave written
consent on behalf of the patient. This consent procedure was
approved by Research and Ethics Committee.
Results
During the study period a total of 289 drug resistant TB
patients were enrolled at the study site. A total of 46 patients
were excluded: 29 with drug resistant TB other than MDR-TB
(10 with mono-drug resistant TB, six with poly-drug resistant,
and 13 with extensive drug resistant) and 17 with history of
previous treatment for MDR-TB (Fig. 1).
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Table 1 – Patients’ socio-demographic, baseline clinical characteristics and oﬂoxacin resistance.
Variables No. (%) Resistance to oﬂoxacin (No. %) p-Value
Yes No
Gender 0.288
Female 135 (55.6) 67 (49.6) 68 (50.4)
Male 108 (44.4) 61 (56.5) 47 (43.5)
Age (years) 0.441
10–20 71 (29.2) 36 (50.7) 35 (49.3)
21–40 112 (46.1) 57 (50.9) 55 (49.1)
41–60 48 (19.8) 26 (45.2) 22 (45.8)
>60 12 (4.9) 9 (75) 3 (25)
Nationality 0.828
Pakistani 223 (91.8) 117 (52.5) 106 (47.5)
Afghan 20 (8.2) 11 (55) 9 (45)
Residence 0.648
Rural 187 (77) 100 (53.5) 87 (46.5)
Urban 56 (23) 28 (50) 28 (50)
Marital status 0.028
Unmarried 114 (46.9) 51 (44.7) 63 (55.3)
Married 116 (47.7) 67 (57.8) 49 (42.2)
Widow 13 (5.3) 10 (76.9) 3 (32.1)
Smoking 0.157
Non-smokers 212 (87.2) 108 (50.9) 104 (49.1)
Active + ex-smokers 31 (12.7) 20 (64.5) 11 (35.5)
Co-morbidity 0.837
No 208 (85.6) 109 (52.4) 99 (47.6)
Yes 35 (14.4) 19 (54.3) 16 (45.7)
Close contact TB status 0.164
No TB 175 (72) 98 (56) 77 (44)
Drug susceptible TB 36 (14.8) 14 (38.9) 22 (61.1)
Drug resistant TB 32 (13.2) 16 (50) 16 (50)
Baseline weight (kg) 0.229
≤40 92 (37.9) 53 (57.6) 39 (42.4)
>40 151 (62.1) 75 (49.7) 76 (50.3)
Baseline chest X-ray 0.398
No cavitations 96 (39.5) 73 (50.7) 71 (49.3)
Cavitations 144 (59.3) 54 (56.2) 42 (43.8)
Registration category 0.002
New 21 (8.6) 5 (23.8) 16 (76.2)
Relapse 33 (13.6) 21 (63.6) 12 (36.4)
Treatment failure 183 (67.1) 82 (50.3) 81 (49.7)
Default 3 (1.2) 3 (100) 0 (0)
Other 23 (9.5) 17 (73.9) 6 (26.1)
Previous TB treatment center 0.002
Public 133 (54.7) 64 (48.1) 69 (51.9)
Private 68 (28) 44 (64.7) 24 (35.3)
Public–private mix 21 (8.6) 15 (71.4) 6 (28.6)
No history of TB treatment 21 (8.6) 5 (23.8) 16 (76.2)
History of SLD use 1.112
No 231 (95.1) 119 (51.5) 112 (48.5)
Yes 12 (4.9) 9 (75) 3 (25)
Smear grading at baseline 0.199
Negative 16 (6.6) 5 (31.2) 11 (68.6)
Scantya, +1b 14 (18.1) 24 (54.5) 20 (45.5)
+2c, +3d 180 (74.1) 98 (54.4) 82 (45.6)
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Table 1 – (Continued )
Variables No. (%) Resistance to oﬂoxacin (No. %) p-Value
Yes No
Site of TB 0.515*
Pulmonary 238 (97.9) 125 (52.5) 113 (47.5)
Extra-pulmonary 3 (1.2) 1 (33.3) 2 (66.7)
Pulmonary + extra-pulmonary 2 (0.8) 2  (100) 0 (0)
a 1–9 Acid Fast Bacilli (AFB)/100 High Power Field (HPF).
b 10–99 AFB/100 HPF.
c 1–9 AFB/HPF.
d >9 AFB/HPF, kg, kilogram; SLD, second line drugs.Socio-demographic  and  clinical  characteristics  of  study
subjects
Mean age of patients was 30.4 ± 14.4 years. Socio-
demographic, baseline clinical and microbiological
characteristics of 243 patients included in the study are
given in (Table 1).
Anti-tuberculosis  drug  susceptibility  patterns
A high degree of drug resistance (median ﬁve drugs, range 2–8)
was observed. Among three ﬁrst-line anti-TB drugs (PZA, E,
and S), the rate of resistance was highest for PZA (97.5%) fol-
lowed by E (81.1%) and S (70%). High proportion of patients
was resistant to all ﬁve ﬁrst-line anti-TB drugs (62.6%) and
SLD (55.1%). Resistance to Ofx was observed in 52.7% patients.
Sputum isolate from four patients (1.6%) was resistant to two
drugs (HR), 18 (7.4%) to three drugs (16 to HRZ, 1 to HRS, and
1 to HRE), 33 (13.6%) to four drugs (13 to HREZ, 12 to HRZS,
7 to HRZ + ofx, 1 to HRE + Ofx), 96 (39.5%) to ﬁve drugs (62 to
HREZS, 28 to HREZ + Ofx, 5 to HRZS + Ofx, 1 to HREZ + Eto),
83 (34.2%) to six drugs (78 to HREZS + ofx, 2 to HREZS + Eto, 1
HREZS + Cm,  1 to HREZ + Ofx + Eto, 1 to HRZ + Am + Km + Cm),
eight to (3.3%) to seven drugs (HREZS + Ofx + Eto) and one to
eight drugs (HREZS + Am + Km + Cm)  (Table 2).
Table 2 – Anti-tuberculosis drug susceptibility patterns.
Variables No. (%)
Drugs resistance at baseline visit
2–4 drugs 55 (22.6)
5–6 drugs 179 (73.7)
>6 drugs 9 (3.7)
Resistance to pyrazinamide 236 (97.1)
Resistance to ethambutol 197  (81.1)
Resistance to streptomycin 170 (70)
Resistance to all ﬁve ﬁrst line drugs 153 (62.6)
Resistance to second line drugs 134 (55.1)
Resistance to oﬂoxacin 128 (52.7)
Resistance to ethionamide 13 (6.6)
Resistance to capreomycin 3 (1.2)
Resistance to amikacin 2 (0.8)
Resistance to kenamcyin 2 (0.8)Predictors  of  oﬂoxacin  resistance
In the univariate analysis, patient marital status, history of
TB treatment, registration category, and center(s) that had
provided previous TB treatment were signiﬁcantly associated
with Ofx resistance. In multivariate analysis, Ofx resistance
had statistically signiﬁcant positive association with previ-
ous TB treatment at private (OR = 1.953, p = 0.034) and public
private mix  (PPM) (OR = 2.824, p = 0.046) sectors (Table 3).
Discussion
The present study revealed a high degree of drug resistance.
The majority of MDR-TB patients (62.6%) were resistant to all
ﬁve ﬁrst line anti-TB drugs, and more  than half (55.1%) were
resistant to SLD. FQ resistance in MDR-TB patients observed
in present study (52.7%) was much higher than that reported
in the Global Tuberculosis Report 2014 (17%),6 but is in line
with reported increase of FQ resistance in MDR-TB patients in
Pakistan (17.4% in 2005, 42.9% in 2009, and 53.9% in 2014).7,8
High rate of FQ resistance observed in current study, and its
gradual increase in drug resistant TB in the country makes it
an alarming issue. This could be attributed to many  factors.
Patients’ prior exposure to FQ has been cited as one reason
for FQ resistant Mycobacterium tuberculosis (MTB) strains.11,12 A
recent meta-analysis concluded that there is threefold greater
risk of FQ resistance among TB patients who  are exposed to
FQ before diagnosis of TB.13 Reports from Pakistan and other
developing countries attribute to frequent self medication of
chest symptomatics in the community before they are actu-
ally diagnosed with TB and put on appropriate treatment.14–17
A median of more  than 12 weeks delay between onset of
TB symptoms and presentation at a TB treatment center has
been reported by studies conducted in Pakistan.16,17 Because
of easy access and low or no consultation fee, most poor
patients in Pakistan with inadequate awareness about TB
initially prefer local paramedics for seeking treatment for
respiratory tract infections.18 On the other hand, patients hav-
ing the ﬁnancial means, due to easy access, short waiting
periods, care givers better attitudes, and stereotyping private
health sector as a provider of high quality care prefer private
practitioners.16,17 Due to lack of diagnostic facilities and inad-
equate knowledge,19,20 paramedics and private practitioners
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Table 3 – Predictors of oﬂoxacin resistance.
Variables Oﬂoxacin resistance Univariate analysis p-Value Multivariate analysis p-Value
No (%) OR (95%CI) OR (95%CI)
Gender
Female 135 (55.6) Referent
Male 108 (44.4) 1.317 (0.792–2.190) 0.288
Age (years)
10–20 71 (29.2) Referent
21–40 112 (46.1) 1.008 (0.556–1.826) 0.980
41–60 48 (19.8) 1.149 (0.551–2.394) 0.711
>60 12 (4.9) 2.917 (0.729–11.675) 0.130
Nationality
Pakistani 223 (91.8) Referent
Afghan 20 (8.2) 1.107 (0.442–2.777) 0.828
Residence
Rural 187 (77) Referent
Urban 56 (23) 0.870 (0.479–1.581) 0.648
Marital status
Unmarried 114 (46.9) Referent Referent
Married 116 (47.7) 1.689 (1.003–2.846) 0.049 1.589 (0.921–2.741) 0.096
Widow 13 (5.3) 4.118 (1.076–15.757) 0.039 3.536 (0.903–13.848) 0.070
Smoking
Non smokers 212 (87.2) Referent Referent
Active + ex-smokers 31 (12.7) 1.751 (0.800–3.833) 0.161 1.649 (0.727–3.739) 0.231
Co-morbidity
No 208 (85.6) Referent
Yes 35 (14.4) 1.079 (0.526–2.213) 0.837
Close contact TB status
No TB 175 (72) Referent Referent
Drug susceptible TB 36 (14.8) 0.500 (0.240–1.041) 0.064 0.686 (0.288–1.637) 0.396
Drug resistant TB 32 (13.2) 0.786 (0.369–1.671) 0.531 0.832 (0.371–1.863) 0.654
Baseline weight (kg)
≤40 92 (37.9) Referent
>40 151 (62.1) 0.726 (0.431–1.224) 0.230
Baseline chest X-ray
No cavitations 96 (39.5) Referent
Cavitations 144 (59.3) 1.250 (0.744–2.101) 0.399
Registration category
New 21 (8.6) Referent Referent
Relapse 33 (13.6) 5.600 (1.638–19.147) 0.006 0.550 (1.046–2.608) 0.376
Treatment failure 183 (67.1) 3.240 (1.134–9.258) 0.028 0.339 (0.129–1.237) 0.112
Other 26 (10.7) 10.667 (2.747–41.423) 0.001
Previous TB treatment center
Public 133 (54.7) Referent 0.027 Referent 0.034
Private 68 (28) 1.197 (1.082–3.611) 0.053 1.953 (1.053–3.624) 0.046
Public–private mix 21 (8.6) 2.695 (0.986–7.331) 0.044 2.824 (1.021–7.182) 0.075
No history of TB treatment 21 (8.6) 0.337 (0.117–0.973) 0.378 (0.130–1.104)
History of SLD use
No 231 (95.1) Referent Referent
Yes 12 (4.9) 2.824 (0.745–10.996) 0.127 2.164 (0.542–8.642) 0.275
Smear grading at baseline
Negative 5 (31.2) Referent 0.117 Referent
Scantya, +1b 24 (54.5) 0.785–8.874 0.084 2.276 (0.641–8.082) 0.203
+2c, +3d 98 (54.4) 0.878–7.876 2.137 (0.675–6.766) 0.197
a 1–9 acid fast bacilli (AFB)/100 high power ﬁeld (HPF).
b 10–99 AFB/100 HPF.
c 1–9 AFB/HPF.
d >9 AFB/HPF, kg, kilogram; SLD, second line drugs.
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often prescribe pharmacy driven broad spectrum FQ21 before
referring patients to TB treatment centers to be treated. This
shopping around of patients, and exposure to FQ before TB
diagnosis is one of the most likely reason for high FQ resis-
tance in TB patients in Pakistan. Non-prescription sale of
FQ,22 its widespread use by general practitioners for lower
respiratory tract infections other than TB,7,23 and availabil-
ity of counterfeit and substandard preparations in developing
countries24,25 are other possible reasons for high FQ resis-
tance in TB patients in these countries. Although in the
present study very few patients had the documented record
of previous use of FQ, but due to its easy availability,22 and
frequent prescription by clinicians for respiratory tract infec-
tions in the country, previous use of FQ in these patients
cannot be ruled out. Failure to keep the minimum essential
records of TB patients particularly in private health sector,19
and over-the-counter availability of FQ in the country22 make
it difﬁcult to trace history of previous use of FQ in TB
patients.
In current study multivariate analysis showed previous
TB treatment at private sector as a risk factor for FQ resis-
tance in MDR-TB patients. Prescription of FQ to patients when
TB is misdiagnosed with other lower respiratory tract infec-
tions, and inappropriate TB treatment by inadequately trained
professionals in private sector could explain positive associa-
tion between previous TB treatment at a private center and
FQ resistance. Insufﬁcient knowledge of private practition-
ers, deviation from TB management guidelines, inappropriate
regimens, lack of supervision on treatment adherence, and
no action on patient default has widely been reported in
Pakistan.19,20,26 A study conducted at Lahore and Rawalpindi
reported that only one out of 245 private practitioners correctly
identiﬁed cough for >3 weeks alone as the main symptom
suggesting pulmonary TB. Among them, 97% were unaware
of TB treatment categories; all of them (100%) were unaware
of guideline recommended treatment regimen, phases and
duration; and none (0%) was observing DOTS strategy.19 Simi-
larly poor practices by private practitioners have been reported
in India:27,28 only six out of 106 private practitioners wrote a
correct prescription with the correct regimen for TB patients.
Over one third of them prescribed a single SLD which was an
FQ in 70% cases.27 Similarly, 105 private practitioners were
reported to prescribe 79 different regimens for treating TB
containing very few guidelines compliant regimens.28 In addi-
tion, the huge and unregulated private sector of sub-standard
anti-TB drugs (including FQ) is another contributing factor
in development of FQ resistance.24,25 A study conducted in
10 TB high burden countries (including Pakistan) found that
at least one third of all private sector dosages of ﬁrst-line
TB drugs fell outside of national and international treatment
recommendations.25
In the present study, previous TB treatment at PPM sec-
tor also emerged as risk factor for FQ resistance. In Pakistan,
the PPM strategy for TB management was initiated in 2006;
and at present it engages 2300 private health care providers.
The majority of PPM centers in the country involve for-proﬁt-
qualiﬁed private practitioners, where drugs are given free of
cost to patients they are but charged for consultation. Very few
studies have evaluated the effectiveness of PPM regarding case
detection rate and TB treatment outcomes in Pakistan.18,29,30 0 1 6;2  0(1):41–47
A study conducted at a PPM center in Karachi has reported
national ﬁgures comparable treatment success rate (86.3%),
but a high default rate (8.7%) in TB patients.30 Similar TB treat-
ment success rate of 87% in patients treated at PPM sector has
been reported by another study conducted in the same city.18
Despite training, frequent interaction, and authors’ regular
visits to study sites, in both studies only half of the practi-
tioners enrolled remained active and committed.18,30 Due  to
scarcity of publication on practitioners’ knowledge and adher-
ence to national guidelines for TB management at PPM in the
country, it is difﬁcult to explain the association between pre-
vious TB treatment at PPM centers and FQ resistance. The
inertia of previous practice, charging fee for every visit, lack of
proper supervision of treatment adherence, and practitioners’
low level of commitment at PPM sector18,30 may have resulted
in inappropriate and irregular TB treatment and, in turn, FQ
resistance. However this ﬁnding needs further investigation.
In current study due to high prevalence of FQ resistance,
predominant TB type was Pre-XDR-TB (MDR-TB + resistance
to FQ). This brought the suitability of the guidelines rec-
ommended standardized regimen (Am/Km-Lfx-Eto-Cs-Z) in
patients in to question.31 Initiating therapy with Am/Km-Lfx-
Eto-Cs-Z will result in suboptimal regimen (<4 active or likely
active SLD) in the majority of patients until the availability of
DST results, which by conventional method usually takes 6–8
weeks. This delay in initiating optimal regimen may result in
poor treatment outcomes, ampliﬁcation of further resistance,
conversion of pre-XDR to XDR-TB, and its transmission in
community. In the light of ﬁndings from the present previously
conducted large studies,7,8 we suggest that the National Tuber-
culosis Control Program should evaluate MDR-TB patients’
countrywide data for FQ resistance. If the present ﬁndings
are conﬁrmed, then WHO  updated recommended regimen
(Am/Cm-Lfx-Eto-Cs-PAS-Z) for initiating treatment in MDR-
TB patients in settings of high SLD resistance32 should be
adopted.
Although at the time of study initiation PMDT unit LRH
was the only center in Khyber Pukhtoonkhwa (one of the four
provinces of Pakistan) where MDR-TB was treated, but being
study from a single center, and limited sample size, its results
cannot be generalized. A multicenter study with larger sample
size is suggested to conﬁrm the present ﬁndings.
Conclusion
Considering the burden of MDR-TB in Pakistan and the impor-
tance of FQs in treating drug-resistant TB, the high prevalence
of FQ resistant MDR-TB patients observed in this study is
alarming. The adoption of more  restrictive policies to control
non-prescription sale of FQ, and its rational use by physicians,
is urgently needed to prevent further increase in FQ resis-
tant MTB  strains. In order to stop the further escalation of
FQ resistance in Pakistan, we recommend that the country
should increase its efforts to increase public awareness about
TB and the hazards of self-medication with antibiotics; trainprivate and PPM sectors; and to develop people trust on pub-
lic health sector by making it more  extensive, appealing, and
ﬂexible.
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